CD8A and non-small cell lung carcinoma: However, it is worth emphasizing some of the significant differences which may be relevant in the context of exacerbation of inflammation in the impairment of the antitumor immune response, such as the CD16 (FcγRIII) decrease both in CD4+ NKT and CD8+ NKT cells in NSCLC compared with SmHC (Supplementary Figure 7).